FiercePharma

TEVA ANNOUNCES COPAXONE® REACHES ONE MILLION PATIENT YEARS OF EXPERIENCE IN THE TREATMENT OF MULTIPLE SCLEROSIS

Approved in 1996, Copaxone® is the global market leader in the treatment of relapsing-remitting multiple sclerosis (RRMS) Ongoing, prospective, clinical trial follow-up reinforces the established ...
RAPS

Teva Calls on FDA to Make Copaxone a Biologic as Part of March Transition

Beginning 23 March, the US Food and Drug Administration (FDA) is going to convert more than 100 medicines approved under new drug applications (NDAs) to biologics license applications (BLAs) because ...
Mint

Teva sues FDA over bid to block approval of generic Copaxone

Copaxone brings in $3.2 billion in annual US sales and accounts for more than half of Teva's profit. Photo: Wikimedia Commons Wilmington, Delaware: Teva Pharmaceutical Industries Ltd sued US ...
Reuters

Third U.S. patent on Teva's MS drug Copaxone invalidated

NEW YORK (Reuters) - Teva Pharmaceutical Industries on Thursday lost a third patent for its top-selling multiple sclerosis treatment as U.S. patent officials ruled that Copaxone did not deserve legal ...
Washington Examiner

Court backs Teva patents on MS drug Copaxone

Shares of Teva Pharmaceutical Industries Ltd. climbed Monday in the first trading day after a federal court reaffirmed patents protecting the drugmaker’s biggest brand-name product, the multiple ...